Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. [2] [4] Lecanemab is an amyloid beta-directed antibody. [2] It is given via intravenous infusion to patients with mild cognitive impairment or mild dementia. [2]

Lecanemab (Leqembi®) is an antibody intravenous (IV) infusion therapy that targets and removes beta-amyloid from the brain. It has received traditional approval from the U.S. Food and Drug Administration (FDA) to treat early Alzheimer's disease, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...

2022年11月29日 · Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils, is being tested in persons with early Alzheimer’s disease.

2023年8月30日 · The drug lecanemab appears to slow mental decline in people with early Alzheimer's disease. Learn whether it might be right for you. Lecanemab (Leqembi) is a medicine given to slow the progression of mild Alzheimer's disease (AD). This medicine reduces clumps of proteins called amyloid-beta proteins that play a key role in AD.

2023年7月24日 · The Food and Drug Administration (FDA) recently granted full approval to a new Alzheimer’s treatment called lecanemab, which has been shown to moderately slow cognitive and functional decline in early-stage cases of the disease.

2025年1月28日 · What is Lecanemab? Lecanemab (Leqembi) is used for Alzheimer’s disease to help slow the progression of dementia in patients who have mild cognitive impairment (MCI) or mild dementia symptoms. Lecanemab infusion works by reducing amyloid beta (Aβ) plaques and protofibrils in the brain, which helps slow down the worsening of dementia symptoms ...

3 天之前 · Lecanemab has been approved in the U.S., 2 Japan, 3 China, 4 South Korea, 5 Hong Kong, 6 Israel, 7 the United Arab Emirates, 8 the United Kingdom, 9 Mexico, 10 Macau, Oman and Taiwan, and is under regulatory review in 15 countries and regions including the EU. In January 2025, the supplemental Biologics License Application (sBLA) for ...

2023年1月5日 · Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils, is being tested in persons with early Alzheimer's disease.

Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer’s disease. The drug works by...

2025年3月1日 · Lecanemab-irmb injection is used to treat Alzheimer's disease. This medicine is to be given only by or under the supervision of your doctor.